BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jun 27, 2016
Emerging Company Profile

Next-gen NMDA

Why Aptinyx aims to modulate rather than block NMDA receptor activity
BioCentury | Dec 5, 2005
Clinical News

XY 2401: Phase I started

BioCentury | Jun 27, 2005
Product Development

Back to bradykinin

BioCentury | Jan 17, 2005
Company News

Rottapharm S.p.A., Xytis Pharmaceuticals deal

Items per page:
1 - 4 of 4